Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Conclusion br In this study we have

    2022-09-07


    Conclusion
    In this study we have shown ALU A 61603 115 and 247 levels in serum are elevated in breast and prostate cancer patients compared to their counterpart healthy controls. DNA integrity was higher in prostate cancer patients than the control but in breast cancer patients it is lower compared to their control counterparts. In prostate but not in breast cancers, DNA integrity increased with dis-ease severity and higher staging. These results largely conform to published reports, and further boosts hope of the diagnostic and prognostic utility of ccfDNA and DNA integrity in cancers. It holds potential and more re-search effort should be dedicated to the area. We however, express that our investigations are preliminary and need an extension into a larger sample size for validation.
    Acknowledgments
    We are thankful to staff of MDS Lancet Laboratory Ghana, and Department of Surgery and the Chemotherapy Unit of the Korle-Bu Teaching Hospital who helped tremendously with patient recruitment and sample collection. The laboratories of the Department of Biochemistry, Cell and Molecular Biology, University of Ghana, were used for successful laboratory ex-perimentation and we appreciate the faculty and all support staff (administrative and laboratory) who helped in wonderful ways to make this project a success.
    Conflict of interest
    The authors declare that they have no conflict(s) of interest regarding this manuscript.
    Author contribution
    Conceptualization: BAB, RMB, NAA
    Design, Data Generation & Data Analysis: ESDS, ABD,
    ANAA, EDAO, BAB
    Manuscript Development: NAA, BAB, EAT, ANAA, EDAO  B. Arko-Boham, N.A. Aryee and R.M. Blay et al.
    Supplementary material
    References
    [9] Asiedu-Addo SK, Nwi-Mozu I, Ali M. Modeling the survival of retrospective clinical data from prostate cancer patients in Komfo Anokye Teaching Hospital, Ghana. Int J Appl Sci 2015;5(6). [10] Cho H, Mariotto AB, Schwartz LM, Luo J, Woloshin S. When do changes in cancer survival mean progress? The in-sight from population incidence and mortality. JNCI Monogr 2014;2014(49):187–97.
    [14] Iqbal S, Vishnubhatla S, Raina V, Sharma S, Gogia A, Deo SS, Mathur S, Shukla NK. Circulating cell-free DNA and its in-tegrity as a prognostic marker for breast cancer. Springerplus 2015;4(1):265.
    Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers 71
    [18] Jahr S, Hentze H, Englisch S, Hardt D, Fackelmeyer FD, Hesch RD, Knippers Rl. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659–65. [19] Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DS. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006 2006;24(26):4270–6.
    [23] Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riis-naes R, Massard C, Cassier PA, Miranda S, Clark J, Den-holm KA, Thway K, De Castro DG, Attard G, Molife LR, Kaye SB, Banerji U, de Bono JS. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 2012;7(11):e47020.
    [26] Vizza E, Corrado G, De Angeli M, Carosi M, Mancini E, Baiocco E, Chiofalo B, Patrizi L, Zampa A, Piaggio G, Cic-chillitti L. Serum DNA integrity index as a potential molecu-lar biomarker in endometrial cancer. J Exp Clin Cancer Res 2018;37(1):35.
    [27] Volik S, Alcaide MM, Morin RD, Collins C. Cell-freeDNA (cfDNA): clinical Significance and utility in cancer shaped by emerging technologies. Mol Cancer Res 2016:898–908.
    Contents lists available at ScienceDirect
    Journal of Biotechnology
    journal homepage: www.elsevier.com/locate/jbiotec
    Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer